Polarean Imaging plc announced that it has partnered with VIDA Diagnostics. The companies are partnering to further enable the Polarean xenon 129 MRI platform to accelerate clinical and research use. VIDA has empowered more than 1,000 clinical and research sites globally with its imaging management platform, a cloud-native AI-enabled solution that drives standardisation and efficiencies in clinical trial imaging operations.

The platform includes a unique orchestration engine used to integrate and optimise multimodality clinical algorithms and enable new high-quality imaging biomarkers to be more accessible to researchers, and clinical trials, as well as adopted into the clinical care workflows. The collaboration between Polarean and VIDA is intended to support the integration of xenon 129 MRI workflow into the clinical continuum of care to establish a clinical trial network for pharma-sponsored drug and device development using standardised xenon 129 MR image acquisition and data-sharing methods, and to create automated image processing workflows and algorithms. These new products and services will be utilised to expand access to xenon 129 MRI as a lung imaging service and to investigate new indications and biomarkers in broader populations with unmet medical needs. Additionally, through this collaboration, each company will foster new research collaborations and amplify the opportunities it can bring to its lung imaging customers.